HUTCHMED (China) Limited will present new and updated data from compounds discovered by the company at the European Society for Medical Oncology Congress 2026 in Madrid from October 23 to 27. Two positive Phase III studies of savolitinib plus osimertinib, an all-oral, chemotherapy-free combination, have been selected for oral presentations in late-breaking sessions. Global SAFFRON data will be presented in the Presidential Symposium, while China-based SANOVO results will appear in a Proffered Paper session. SAFFRON evaluated patients with EGFR-mutated non-small cell lung cancer, or NSCLC (a common lung-cancer category), with MET overexpression or amplification after disease progression on osimertinib. HUTCHMED reported on August 17, 2026, that the study produced statistically significant and clinically meaningful improvements in progression-free survival and overall survival versus doublet platinum-based chemotherapy. SANOVO studied previously untreated patients with locally advanced or metastatic NSCLC carrying activating EGFR mutations and MET overexpression. HUTCHMED reported positive high-level results on August 31, 2026, showing a statistically significant and clinically meaningful progression-free-survival improvement and a clinically meaningful overall-survival benefit versus osimertinib alone. Additional presentations will cover fruquintinib, surufatinib and investigator-initiated studies across colorectal, renal, pancreatic, ovarian, breast, gastric, esophageal, rectal, neuroendocrine, biliary, small-cell lung and sarcoma cancers. HUTCHMED also outlined the commercial status and development rights for its medicines and cautioned that its forward-looking statements are subject to clinical, regulatory, safety, supply, funding and market risks.